Lead Product(s) : Ricolinostat
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Cobro Ventures
Deal Size : $30.0 million
Deal Type : Series A Financing
Regenacy Pharmaceuticals Raises $30 Million in Series A Financing
Details : Regenacy plans to use the proceeds to initiate a Phase 2 proof-of-concept trial for ricolinostat, an oral, selective histone deacetylase 6 (HDAC6) inhibitor, in diabetic peripheral neuropathy.
Product Name : ACY-1215
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 25, 2020
Lead Product(s) : Ricolinostat
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Cobro Ventures
Deal Size : $30.0 million
Deal Type : Series A Financing